FAAH Inhibitor

PF 750 is a selective, covalent and brain-penetrant fatty acid amide hydrolase (FAAH) inhibitor. PF 750 covalently carbamylates FAAH's catalytic serine nucleophile to inactivate the enzyme.

FAAH-IN-2 (O-Desmorpholinopropyl Gefitinib) is an inhibitor of FAAH. FAAH-IN-2 is a metabolite of Gefitinib (HY-50895).

AKU-005 is a FAAH and MAGL dual inhibitor with IC₅₀ values of 63, 389 nM for rat and human FAAH, respectively. AKU-005 has the potential for the research of trigeminal hyperalgesia.

AA38-3 is a serine hydrolase (SH) inhibitor. AA38-3 can inhibit three SHs, ABHD6, ABHD11, and FAAH.

AM6701 is a potent FAAH/MAGL inhibitor (equipotent inhibitory IC₅₀: 1.2 nM) with neuroprotective effects.

N-(3-Methoxybenzyl)Palmitamide is a promising inhibitor of FAAH for the treatment of pain, inflammation and CNS degenerative disorders.

FAAH inhibitor 1 (compound 3) is a selective reversible FAAH inhibitor. FAAH inhibitor 1 has no off-target activity with respect to other serine hydrolases. FAAH inhibitor 1 is exclusively specific against FAAH in rat brain with an IC₅₀ value of 18 nM and had no missing protein bands in all the other tissues. FAAH inhibitor 1 can be used for neurological disorders research.

FAAH-IN-6 (compound 21d) is a potent, orally active and cross the blood-brain barrier fatty acid amide hydrolase (FAAH) inhibitor with IC₅₀s of 0.72, 0.28 nM for hFAAH, rFAAH, respectively. FAAH-IN-6 shows dose-dependent analgesic efficacy in animal models of both neuropathic and inflammatory pain.

FAAH/MAGL-IN-4 (Compound 13) is a potent fatty acid amide hydrolase (FAAH) and monoglyceride lipase (MGL) inhibitor with IC₅₀s of 9.1 nM and 7.9 μM, respectively. FAAH/MAGL-IN-4 can be used for the research of pain and CNS disorders.

Irafamdastat (BMS-986368) (Example 74) is a FAAH and MAGL inhibitor, with IC₅₀s ≤ 100 nM (human FAAH) and 100 nM-1 μM (human MAGL) respectively. Irafamdastat has antiepileptic effect.

N-Arachidonoylserotonin (Arachidonyl serotonin) is a dual FAAH inhibitor and TRPV1 antagonist. N-Arachidonoylserotonin blocks Anandamide (HY-10863) hydrolysis, increases brain Anandamide levels, and promotes CB1 receptor signaling in the dorsal hippocampus. N-Arachidonoylserotonin normalizes HPA axis dysregulation, reduces plasma corticosterone levels, and induces anxiolytic-like effects in mice. N-Arachidonoylserotonin reverses behavioral despair, inhibits contextual fear memory retrieval, and produces dose-dependent antinociceptive effects in rodents. N-Arachidonoylserotonin inhibits intestinal motility. N-Arachidonoylserotonin can be used to study stress-related disorders, traumatic memory and related psychiatric disorders, pain, and intestinal motility disorders.

FAAH-IN-1 is a fatty acid amide hydrolase (FAAH) inhibitor, with IC₅₀s of 145 nM and 650 nM for rat and human FAAH, respectively.

Biochanin A (Standard) is the analytical standard of Biochanin A. This product is intended for research and analytical applications. Biochanin A is a naturally occurring fatty acid amide hydrolase (FAAH) inhibitor, which inhibits FAAH with IC₅₀s of 1.8, 1.4 and 2.4 μM for mouse, rat, and human FAAH, respectively.

CB2R/FAAH modulator-3 (compound 27) is a dual targeting modulator that acts as a CB2R agonist and FAAH inhibitor. The K_i values for CB2R/FAAH modulator-3 are 20.1 and 67.6 nM for CB2R and CB1R, respectively, and the IC₅₀ value for FAAH is 3.4 μM. CB2R/FAAH modulator-3 can be used in studies related to cancer, deleterious inflammatory cascades occurring in neurodegenerative diseases, and COVID-19 infection.

SA 47 is a selective fatty acid amide hydrolase (FAAH) inhibitor. SA 47 inhibits FAAH enzyme activity and disrupts the NLRP3-FAAH interaction, promoting K48 ubiquitination and selective autophagic degradation of NLRP3. SA 47 reduces NLRP3 protein levels in macrophages. SA 47 can be used for research on inflammatory diseases associated with NLRP3 protein mutations.

N-​Benzyllinolenamide is a natural macamide isolated from Lepidium meyenii, acts as an inhibitor of fatty acid amide hydrolase (FAAH) with an IC₅₀ of 41.8 μM.

JNJ-40355003 is a potent and selective atty acid amide hydrolase (FAAH) inhibitor.

JP83 is an irreversible fatty acyl amide hydrolase (FAAH) inhibitor with an IC₅₀ of 1.6 nM in competitive activity-based protein profiling (ABPP) experiments.

SSR411298 is an orally active, selective and reversible fatty acid amide hydrolase (FAAH) inhibitor. SSR411298 has the potential for post-traumatic stress disorder research.

JP104, a aryl carbamate, is an irreversible FAAH inhibitor with a pIC₅₀ of ~8.